atients with lower extremity peripheral artery disease (PAD) experience substantial functional disability due to claudication, rest pain, and the loss of tissue integrity in the distal limbs. [1] [2] [3] [4] Exercise rehabilitation, drug therapy, and percutaneous or surgical revascularization are the current therapeutic options for these patients. 2, 5 The outcome of percutaneous peripheral intervention (PPI) depends on the anatomic location of the target lesions. For example, PPI for suprainguinal lesions provides a low morbidity and excellent long-term vessel patency, 6 whereas PPI for infrainguinal lesions is associated with a high restenosis rate. In fact, for superficial femoral arteries (SFA), restenosis occurs in up to 60% of cases at 1 year after PPI. [7] [8] [9] Therefore, PPI for infrainguinal lesions has been confined to unusual circumstances, such as when patients are high risk for surgical treatment. 10 In recent years, with continuing advances in imaging techniques, angioplasty equipment, and endovascular expertise, patients with SFA occlusive disease have undergone a shift in management to include PPI as a primary treatment strategy. 9, [11] [12] [13] [14] Yet, there are no data to support the assumption that PPI for SFA results in lasting benefit in these patients.
Accordingly, in the current study, we retrospectively reviewed the long-term outcome of patients with SFA occlusive disease. The results indicate that for these patients, PPI does not provide superior long-term benefit compared with conservative medical therapy, suggesting that medical therapy still remains a viable primary treatment strategy for this group of patients. To our knowledge, this is the first report that directly compares the long-term outcome of PPI with medical therapy for patients with SFA occlusive disease.
ously undergone PPI or bypass surgery were excluded.
PPI Procedure
Indications for PPI were made by several cardiologists, surgeons and interventional radiologists at our hospital after considering patients' clinical status. Briefly, angiography was reviewed and SFA lesions were categorized under the modified TransAtlantic Inter-Society Consensus (TASC) system (Table 1) . PPI was considered when a patient had Fontaine grade II symptoms with the lesion morphologies of TASC types A and B, or when a patient had Fontaine grade III or IV symptoms (ie, critical limb ischemia). PPI was also considered regardless of the lesion morphologies if a patient did not tolerate claudication symptoms under optimal drug therapy.
All PPI procedures were performed under systemic administration of heparin. Conventional balloon angioplasty was carried out as a primary strategy. Stent implantation was not routinely performed, but was considered when the lesions showed either flow-limiting dissections, a stenosis diameter of >30%, or acute closure. Procedural success was defined as having a stenosis diameter of <30%, pressure gradients of the lesion of <10 mmHg, or improvement in ankle -brachial pressure index (ABI) of >0.10. When there were no contraindications, patients undergoing PPI were prescribed aspirin as well as at least one other antiplatelet or anticoagulant agent. If worsening or recurrence of limb symptoms was observed during the follow-up period, patients received ultrasound and/or angiographic assessment to ascertain restenosis of the dilated lesions.
Long-Term Outcome
Clinical records of 107 patients were retrospectively reviewed to determine whether long-term outcome differed between patients undergoing PPI and those receiving conservative medical therapy. Specifically, for each patient, baseline demographic information, limb symptom (Fontaine grade), ABI, comorbidities, atherosclerotic risk factors, and oral medications were identified. When SFA showed diffuse or multiple lesions, the lesion showing the most severe degree of TASC category was assigned as the lesion category for that patient. These baseline clinical variables were statistically analyzed and correlated with long-term adverse events, which included death, limb amputation, re-hospitalization due to worsening of limb symptoms, new onset of coronary artery disease, and new onset of cerebrovascular disease. The information relating to long-term outcome was obtained by means of patients attending an outpatient clinic.
Definitions
Resting ABI was calculated as the quotient of absolute ankle pressure and brachial pressure. Each patient's ABI was measured upon admission and at follow-up. In patients receiving PPI, ABI was also measured after PPI. Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or as taking antihypertensive medications. Dyslipidemia was defined as having a fasting cholesterol of ≥220 mg/dl, low-density lipoprotein of ≥140 mg/dl, high-density lipoprotein of <40 mg/dl, triglycerides of ≥150 mg/dl, or currently taking lipid-lowering medications. Diabetes mellitus was defined as a fasting plasma glucose of ≥126 mg/dl, hemoglobinA1c of ≥6.5%, or currently taking antidiabetic medications. Coronary artery disease was defined as a history of angina pectoris, myocardial infarction, or prior coronary revascularization. Cerebrovascular disease included a history of stroke, transient ischemic attack, or carotid artery revascularization. Chronic renal impairment was defined as a serum creatinine level of ≥2.0 mg/dl, or being on hemodialysis.
Statistical Analysis
Data were expressed as the mean value ± standard deviation. Statistical significance was evaluated using paired and unpaired Student's t-test for comparisons between 2 means, and chi-square test for categorical data. Event-free survival was estimated using the Kaplan -Meier survival method with log-rank statistics. Statistical significance was defined as a p-value of <0.05.
Results

Patient Population
Of the 107 patients with SFA occlusive disease, 55 patients received PPI (ie, PPI group) and 52 underwent conservative medical therapy (ie, control group). Indications for PPI in these 55 patients included critical limb ischemia in 3 patients, and intermittent claudication in 51. Another patient was asymptomatic under pharmacologic therapy; however, PPI was performed based on the patient's request.
Age, gender, follow-up period, Fontaine grade, atherosclerotic risk factors, comorbidities, and ABI on admission were not statistically different between the groups. With regard to lesion characteristics, patients receiving PPI showed less severe types of lesions (ie, TASC types A and B lesions rather than types C and D lesions) compared with those receiving conservative medical therapy (p<0.01) ( Table 2) .
Short-Term Outcomes of PPI
PPI was successfully performed in 50 of 55 patients (90.9%). Forty patients were treated by balloon angioplasty alone, and 10 received stent implantation, including 7 Palmatz stents, 4 Easy Wall stents, and 1 Smart stent. Indications for stent implantation were residual stenosis of >30% in 5 patients and flow limiting dissection in 5. Procedural failure was observed in 5 patients, of whom 3 patients were on chronic hemodialysis. The reasons for the failure were unsuccessful wire crossing in 4 patients, and wire perforation in 1 patient. Lesion characteristics of the failed cases were TASC type B lesion in 2 patients, type C in 2, and type D in 1. Four of the 5 patients had chronic total occlusions of SFA.
Upon discharge, a significantly greater number of antiplatelet and anticoagulant agents were prescribed in the PPI group than in the control group (2.27±0.78 vs 1.87±0.81, p<0.05). This was mainly due to the higher number of patients taking ticlopidine in the PPI group compared with the control group (38.2% vs 7.7%, p<0.001). ABI in the PPI group significantly improved from 0.61±0. 15 (p<0.001), which was also higher than that of the control group (0.61±0.17, p<0.001) ( Table 2) .
Long-Term Outcomes
Long-term outcomes of patients in both groups are shown in Table 3 . The average follow-up periods were 30.6±17.7 months for all patients; 31.6±18.1 months for the PPI group and 29.6±16.8 months for the control group (p=NS). Five patients (9.1%) in the PPI group showed no limb symptoms at follow-up (including 1 patient who had been asymptomatic before PPI), whereas all the control group patients had limb symptoms. On the other hand, 6 (10.9%) of the PPI patients showed ischemic skin ulcer/ gangrene at follow-up; 5 of the 6 had been at Fontaine grade II at baseline, and in 2 of these 5 patients PPI was unsuccessful due to distal embolization and perforation. In contrast, in the control group only 2 patients showed such ischemic skin lesions at follow-up. Both of these patients had these lesions at baseline (Fig 2) . As a result, the average Fontaine grade at follow-up was not different between the PPI and control groups (2.18±0.60 vs 2.12±0.18, p=NS). The finding that patients receiving PPI showed no long-term improvement in the Fontaine grade compared with medical treatment was further supported by the results of the ABI measurements. At follow-up, ABI of the PPI group returned to the baseline level from 0.81±0.20 to 0.61±0.17, and no statistically significant differences were observed between the PPI and control groups (0.60±0.19, p=NS).
Overall, long-term adverse events were more frequent in the PPI group than the control group. Specifically, adverse events were observed in 69.1% (ie, 38/55) of PPI patients compared with 46.2% (ie, 24/52) of control patients (p< 0.05). The increased number of adverse events observed in the PPI group was mainly due to a high frequency of re-hospitalization due to worsening of limb symptoms (52.7% [ Table 2 . 
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val curve free from re-hospitalization. The survival rate was significantly higher in the control group (solid line) than the PPI group (broken line) (p<0.001). The estimated survivals free from re-hospitalization in the control and PPI groups were 95.6% compared with 60.9% at 1 year; and 88.1% compared with 40.0% at 2 years, respectively. Frequencies of death, limb amputation, new onset of coronary artery disease, and new onset of cerebrovascular disease were not statistically different between the 2 groups.
Discussion
Patients with SFA occlusive disease have undergone a shift in management to include PPI as a primary treatment strategy. 9, 11, 12, [14] [15] [16] Yet, there are no data showing that PPI provides lasting benefit that is superior to conservative medical therapy.
PPI has been shown to provide an excellent short-term outcome in patients with SFA occlusive disease. The technical success rate of PPI for femoropopliteal artery stenoses exceeds 90% (range, 73-100%). 17 Even for chronic total occlusions, advances in technology have provided high recanalization rates (range, 68-83%). 18 However, long-term patency of balloon-dilated lesions is suboptimal. For example, Muradin et al recently reported the results of a metaanalysis showing that the combined 3-year patency rates after balloon dilation for femoropopliteal lesions was 61% for patients with stenoses and claudication, 43% for those with stenoses and critical limb ischemia, and 30% for those with occlusions and critical limb ischemia. 19 The 3-year patency rates after stent implantation were similar, ranging from 63% to 66%, and were independent of clinical indication and types of lesions. 19 The short-and long-term results of PPI in the present study are comparable to these previous studies. Procedural success was achieved in >90% of patients, and ABI increased by >30%. Restenosis, however, developed in as many as 36% of patients, reducing the long-term success of PPI. As a result, no long-term benefits, including survival and prevention of limb amputation, were achieved when compared with conservative medical therapy. In addition, more than half of the patients receiving PPI were later re-hospitalized. It should be noted that about twothirds of patients from the PPI group who were re-hospitalized were found to have restenosis. Thus, it is assumed that frequent restenosis after PPI contributed to the increased incidence of re-hospitalization. Although one could argue that more advanced atherosclerosis of the SFA lesions contributed to the more frequent incidence of re-hospitalization in the PPI group, this assumption cannot be supported since patients in the PPI group had less severe lesions than the control group at baseline.
Prospective studies comparing the long-term outcome of PPI compared with medical therapy are limited. 17 Perkins and colleagues reported that despite significant initial improvement in ABI after PPI, there was no significant difference in patients' walking distance between those who had undergone PPI compared with exercise therapy after 70 months of follow-up. 20 Whyman et al also examined the outcome of PPI in patients treated with low-dose aspirin, exercise training, and smoking cessation. 21 After 2 years of follow-up, neither walking distance nor ABI were significantly different between patients who had or had not undergone PPI. It must be noted that these studies included patients with suprainguinal as well as infrainguinal lesions, and were not intended to determine the outcome of PPI for SFA lesions. Considering the fact that PPI for suprainguinal lesions is generally associated with a lower restenosis rate than that for infrainguinal lesions, it appears that PPI for SFA lesions does not achieve a better outcome compared with medical treatment. The current study underscores this assumption by showing that, despite a favorable short-term outcome, PPI does not provide superior long-term benefits compared with conservative medical therapy in patients with SFA occlusive disease, and suggests that medical therapy may continue to remain the primary treatment strategy for this group of patients.
The use of stents in SFA has not been shown to be more beneficial than plain old balloon angioplasty. 16, [22] [23] [24] Thus, the TASC recommends the use of stents only for short SFA lesions and advise that they be used only in bail-out situations. In the present study, based on this recommendation, stents were used only for bail-out situations, and the longterm outcome was comparable to that of the balloon angioplasty. Schillinger et al recently reported that the use of selfexpandable nitinol stents for SFA lesions yielded results that were superior to those of balloon angioplasty. 7 The rate of restenosis on angiography was 24% in the stent group and 43% in the balloon angioplasty group, and at the 1-year follow-up, the rate on duplex ultrasonography was 37% and 63%, respectively. The advantages of nitinol stents include improved radial force, the ability to recover their shape after being crushed, and reduced foreshortening, which allows precise placement. Whether the use of newer-generation stents ultimately leads to better long-term outcomes beyond that presently offered by medical treatment awaits further investigation.
Conclusions
The current study demonstrates that despite a favorable short-term outcome, PPI does not provide superior longterm benefits compared with conservative medical therapy in patients with SFA occlusive disease, suggesting that medical therapy will continue to remain the primary treatment strategy for this group of patients. Kaplan -Meier survival curve of patients free from re-hospitalization. The estimated survivals free from re-hospitalization in patients receiving medical therapy (control group: solid line) and percutaneous peripheral intervention (PPI group: broken line) were 95.6% compared with 60.9% at 1 year; and 88.1% compared with 40.0% at 2 years, respectively.
